Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Orthopedics Attends CHS 2018


Guiyang, China – March 1 to March 4, Shanghai MicroPort Orthopedics Co., Ltd. ("MicroPort® Orthopedics") attended the 2018 Annual Meeting of Chinese Hip Society ("CHS") in Guiyang Province. Jointly hosted by CHS and American Association of Hip and Knee Surgeons ("AAHKS"), the CHS 2018 gathered more than 1,000 domestic and overseas orthopedic experts to exchange ideas on the treatment and surgical technique of hip diseases as well as hot issues related with complex hip replacement surgeries. In the congress, MicroPort® Orthopedics introduced the design rationale and advantages of SuperPath® Micro-posterior Total Hip Arthroplasty ("SuperPath®") through product samples, animation, surgical videos, and instrument demonstration.
In the CHS 2018, MicroPort® Orthopedics hosted a satellite meeting in which Professor Chuan He of Shanghai Ruijin Hospital was invited to introduce SuperPath® surgical technique to the attendees. Professor He said, SuperPath® is a truly minimally invasive surgical technique, not only due to its small incision, but also because it precisely reconstructs the hip without cutting any muscles. Based on his clinical experience with SuperPath®, Professor He explained the surgical steps and tips of SuperPath® and he demonstrated the unparalleled advantages of SuperPath® in fast return to function by case analysis. During the meeting, Professor He said, the learning curve of SuperPath® is much shorter than that of DAA technique, which will offer more clinical benefits to surgeons and patients.
As the world's first total hip arthroplasty minimally invasive technique that facilitates a faster return to function for patients, SuperPath® technique is a milestone in the development of hip replacement. Compared to traditional hip replacement technique, SuperPath® causes incision as little as a 3-inch and ensures the maximum protection of soft tissue. Because of the preservation of external rotators and joint capsule, SuperPath® technique reduces blood loss and tissue damage, leading to fewer post-operative restrictions, faster return to function, and improved satisfaction for patients. SuperPath® technique not only offers patients with small incision, but also preserves the soft tissue to the largest extent which leads to added advantages like preservation of the external rotators, decreased operative time, decreased intra-operative blood loss, increased post-operative stability, as well as decreased post-operative recovery time and pain. Patients can walk as early as four hours after surgery. Recently a 103-year-old patient successfully received SuperPath® surgery in Zhengjiang First People's Hospital, which helped him to stand on his own feet the same day after the surgery. He is the oldest patient to be effectively treated by SuperPath® surgery in China.
The concept of "fast return to function " has been highly recognized by hospitals, clinical experts and medical enterprises as it is in line with the main trend of the development of artificial joint replacement. It improves not only the operative recovery for patients, but also the management efficiency of hospitals so as to save medical resources and sever more patients. In the future, MicroPort® Orthopedics will continue to promote SuperPath® technique and help drive the development of minimally invasive techniques and spread the philosophy of "fast return to function" to benefit more orthopedic patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Attends INDIA LIVE 2018
[Next]:MicroPort® Single-channel ECG Recorder Becomes the First Product Approved According to the Registration Policy